company background image
1167 logo

Jacobio Pharmaceuticals Group SEHK:1167 Stock Report

Last Price

HK$1.82

Market Cap

HK$1.4b

7D

-19.5%

1Y

-49.2%

Updated

12 Oct, 2024

Data

Company Financials +

Jacobio Pharmaceuticals Group Co., Ltd.

SEHK:1167 Stock Report

Market Cap: HK$1.4b

1167 Stock Overview

An investment holding company, engages in the in-house discovery and development of oncology therapies.

1167 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Jacobio Pharmaceuticals Group Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jacobio Pharmaceuticals Group
Historical stock prices
Current Share PriceHK$1.82
52 Week HighHK$4.57
52 Week LowHK$1.38
Beta0.56
11 Month Change5.20%
3 Month Change4.60%
1 Year Change-49.16%
33 Year Change-90.22%
5 Year Changen/a
Change since IPO-87.38%

Recent News & Updates

Recent updates

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

May 29
Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10
We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26
Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29
We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29
We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21
What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Shareholder Returns

1167HK BiotechsHK Market
7D-19.5%-10.1%-6.2%
1Y-49.2%-4.2%17.6%

Return vs Industry: 1167 underperformed the Hong Kong Biotechs industry which returned -4.2% over the past year.

Return vs Market: 1167 underperformed the Hong Kong Market which returned 17.6% over the past year.

Price Volatility

Is 1167's price volatile compared to industry and market?
1167 volatility
1167 Average Weekly Movement10.7%
Biotechs Industry Average Movement10.4%
Market Average Movement8.7%
10% most volatile stocks in HK Market18.5%
10% least volatile stocks in HK Market4.3%

Stable Share Price: 1167 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015298Yinxiang Wangwww.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor.

Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary

How do Jacobio Pharmaceuticals Group's earnings and revenue compare to its market cap?
1167 fundamental statistics
Market capHK$1.44b
Earnings (TTM)-HK$397.95m
Revenue (TTM)HK$25.50m

56.3x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1167 income statement (TTM)
RevenueCN¥23.19m
Cost of RevenueCN¥22.38m
Gross ProfitCN¥801.00k
Other ExpensesCN¥362.69m
Earnings-CN¥361.89m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.46
Gross Margin3.45%
Net Profit Margin-1,560.88%
Debt/Equity Ratio7.0%

How did 1167 perform over the long term?

See historical performance and comparison